Last reviewed · How we verify

Donepezil and Lithium — Competitive Intelligence Brief

Donepezil and Lithium (Donepezil and Lithium) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholinesterase inhibitor + mood stabilizer. Area: Neurology/Psychiatry.

marketed Cholinesterase inhibitor + mood stabilizer Acetylcholinesterase; GSK-3 and intracellular signaling pathways Neurology/Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Donepezil and Lithium (Donepezil and Lithium) — Shanghai Mental Health Center. Donepezil inhibits acetylcholinesterase to increase acetylcholine levels in the brain, while lithium modulates intracellular signaling pathways and neuroprotection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Donepezil and Lithium TARGET Donepezil and Lithium Shanghai Mental Health Center marketed Cholinesterase inhibitor + mood stabilizer Acetylcholinesterase; GSK-3 and intracellular signaling pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholinesterase inhibitor + mood stabilizer class)

  1. Shanghai Mental Health Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Donepezil and Lithium — Competitive Intelligence Brief. https://druglandscape.com/ci/donepezil-and-lithium. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: